Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company specializing in advanced wound care and surgical biologics that entered the public markets through a business combination with Avista Healthcare Public Acquisition Corp, sponsored by Avista Healthcare Partners, which closed in 2018. Headquartered in Canton, Massachusetts, ORGO develops and commercializes products serving hospitals, outpatient wound care centers, and physician offices across the wound care and surgical biologics sectors. The company filed its most recent Form 10-Q with the SEC on May 7, 2026, reporting quarterly results as a fully operating de-SPAC public company. Sign up for SpacDesk to access complete filing histories, deal analytics, and real-time data on Organogenesis and hundreds of other de-SPAC companies.